celecoxib has been researched along with Constriction, Pathological in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In particular, the glycine derivative proved to be extremely active in suppressing hyperalgesia and edema." | 3.80 | Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. ( Alfonso, S; Anzini, M; Battilocchio, C; Biava, M; Calderone, V; Colovic, M; Consalvi, S; Di Capua, A; Di Cesare Mannelli, L; Dovizio, M; Ghelardini, C; Giordani, A; Martelli, A; Patrignani, P; Persiani, S; Poce, G; Rossi, A; Sautebin, L; Testai, L, 2014) |
| "The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported." | 1.38 | Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme. ( Alfonso, S; Anzini, M; Battilocchio, C; Biava, M; Calderone, V; Consalvi, S; Di Cesare Mannelli, L; Ghelardini, C; Giordani, A; Martelli, A; Patrignani, P; Poce, G; Porretta, GC; Rossi, A; Sautebin, L; Schenone, S; Testai, L, 2012) |
| "Mechanical allodynia and thermal hyperalgesia induced by CCI were markedly attenuated by celecoxib from 5 to 14 days after surgery, and relieved by ibuprofen treatment from 7 to 10 days after surgery." | 1.36 | Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats. ( Guo, QL; Huang, CS; Wang, Y; Yan, JQ; Zhang, X; Zou, WY, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biava, M | 3 |
| Porretta, GC | 2 |
| Poce, G | 3 |
| Battilocchio, C | 3 |
| Alfonso, S | 3 |
| Rovini, M | 1 |
| Valenti, S | 1 |
| Giorgi, G | 1 |
| Calderone, V | 3 |
| Martelli, A | 3 |
| Testai, L | 3 |
| Sautebin, L | 3 |
| Rossi, A | 3 |
| Papa, G | 1 |
| Ghelardini, C | 3 |
| Di Cesare Mannelli, L | 3 |
| Giordani, A | 3 |
| Anzellotti, P | 1 |
| Bruno, A | 1 |
| Patrignani, P | 3 |
| Anzini, M | 3 |
| Consalvi, S | 2 |
| Schenone, S | 1 |
| Di Capua, A | 1 |
| Persiani, S | 1 |
| Colovic, M | 1 |
| Dovizio, M | 1 |
| Wang, Y | 1 |
| Zhang, X | 1 |
| Guo, QL | 1 |
| Zou, WY | 1 |
| Huang, CS | 1 |
| Yan, JQ | 1 |
| Chung, JW | 1 |
| Yang, HM | 1 |
| Park, KW | 1 |
| Lee, HY | 1 |
| Park, JS | 1 |
| Kang, HJ | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Koo, BK | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial[NCT00292721] | Phase 4 | 260 participants (Anticipated) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for celecoxib and Constriction, Pathological
| Article | Year |
|---|---|
Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial.
Topics: Aged; Celecoxib; Chemotherapy, Adjuvant; Constriction, Pathologic; Coronary Vessels; Cyclooxygenase | 2010 |
4 other studies available for celecoxib and Constriction, Pathological
| Article | Year |
|---|---|
Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.
Topics: Acetates; Animals; Cell Line; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Edema; Esters; | 2011 |
Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Constriction, Pathologic | 2012 |
Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.
Topics: Acetic Acid; Amides; Animals; Carrageenan; Cell Line; Constriction, Pathologic; Cyclooxygenase 2; Cy | 2014 |
Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.
Topics: Animals; Celecoxib; Constriction, Pathologic; Cyclooxygenase Inhibitors; Ganglia, Spinal; Hot Temper | 2010 |